US Bancorp DE Has $154,000 Position in Zai Lab Limited (NASDAQ:ZLAB)

US Bancorp DE grew its stake in shares of Zai Lab Limited (NASDAQ:ZLAB) by 1,671.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 5,865 shares of the company’s stock after buying an additional 5,534 shares during the period. US Bancorp DE’s holdings in Zai Lab were worth $154,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Y Intercept Hong Kong Ltd acquired a new position in shares of Zai Lab during the third quarter valued at about $225,000. Daiwa Securities Group Inc. raised its position in shares of Zai Lab by 4,851.8% during the third quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock valued at $231,000 after buying an additional 9,364 shares during the last quarter. RBF Capital LLC acquired a new position in shares of Zai Lab during the third quarter valued at about $241,000. China Universal Asset Management Co. Ltd. raised its position in shares of Zai Lab by 15.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company’s stock valued at $290,000 after buying an additional 1,502 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Zai Lab during the third quarter valued at about $325,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

Insider Transactions at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now directly owns 33,834 shares of the company’s stock, valued at $889,157.52. This represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ying Du sold 50,000 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the sale, the chief executive officer now directly owns 494,117 shares in the company, valued at $17,032,212.99. This trade represents a 9.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 122,127 shares of company stock valued at $4,024,442. Corporate insiders own 13.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ZLAB shares. Scotiabank started coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target for the company. Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a research report on Tuesday, March 4th. Bank of America reissued a “neutral” rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. increased their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday.

Zai Lab Trading Up 5.7 %

NASDAQ ZLAB opened at $38.20 on Friday. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -13.79 and a beta of 1.08. The company has a 50 day moving average of $29.47 and a 200-day moving average of $27.13. Zai Lab Limited has a 1-year low of $13.48 and a 1-year high of $39.61.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The firm had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. On average, analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current year.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.